The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency ...

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...

RMAT designation requires preliminary clinical evidence addressing an unmet need in a serious disease and provides Fast Track ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue ...

Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research ...

A curious phenomenon seen by oncologists, that morning patients do better than those receiving afternoon infusions, gains ...

Investigators analyzed economic evaluations of adjuvant immunotherapy to assess cost-effectiveness outcomes, quality-adjusted life-year (QALY)/life-year (LY) gains, and methodologic approaches.

Long-term clinical trials show patients with stage four kidney cancer are living a decade or more beyond previous expectations.

In recent years, cancer researchers have made major breakthroughs by using the body's immune system to fight cancer. One of ...

By analyzing tissue from patients with Parkinson's disease, and animal and cellular models of the disease, a research team ...

Prescribing information and clinical guidelines showed gaps in TB screening protocols for many recently approved targeted immunotherapies.